Product Information

BioFluidica LiquidScan^® Information

DOWNLOAD

LiquidScan^® Oncology Studies

DOWNLOAD

LiquidScan^® STAR(let) Information

DOWNLOAD

Application Notes

Breast Cancer Staging through EV's mRNA

DOWNLOAD

ABOUT BIOFLUIDICA

BioFluidica is a privately held biotechnology company that has developed a revolutionary liquid biopsy platform allowing for the isolation and analysis of all liquid biopsy biomarkers, including rare cells, extracellular vesicles (EVs; exosomes), and cfDNA, on one fully automated platform. The Biofluidica platform has been clinically tested on nine different cancer and prenatal patient samples and is currently used for a large variety of research applications to advance the field of liquid biopsy. The ultralow sensitivity expands the capability of current liquid biopsy applications. We are expert consultants in exosome isolation, fetal cell (trophoblast) isolation, CTC isolation, and next-generation liquid biopsy. We develop and launch innovative scientific instruments, reagents, and software systems designed to provide exceptional value for scientists, clinicians, and patients.

REQUEST INFORMATION

If you have questions or need assistance, our support teams are available and committed to providing the best support we can.

First Name *

Last Name *

Email *

Organization

Phone

Subject *

Message

LEARN MORE

About BioFluidica
Board of Directors
Careers
Product Documents

HEADQUARTERS

Central Innovation Lab:
2029 Becker Dr, Lawrence, KS 66047
World Headquarters:
100 Conway Court, Cary, NC 27513

Scroll to top

Product Information

BioFluidica LiquidScan® Information

LiquidScan® Oncology Studies

LiquidScan® STAR(let) Information

Application Notes

Breast Cancer Staging through EV's mRNA

REQUEST INFORMATION

LEARN MORE

HEADQUARTERS

BioFluidica LiquidScan^® Information

LiquidScan^® Oncology Studies

LiquidScan^® STAR(let) Information